COYA Coya Therapeutics, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$4.55

Period return

-0.18 (-3.81%)

Volume

257.4K

2026-07-21O $4.49 H $4.59 L $4.38 C $4.55MA5 $4.59MA20 $5.24MA60 $4.81MA120 $4.69

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 11.Highin 21 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.00%
2026. 04. 10.LowBUY3 months ago
D. Boral Capital: Buy
US analyst rating / recommendation change.
2026. 03. 23.LowBUY4 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 03. 20.LowBUY4 months ago
D. Boral Capital: Buy
US analyst rating / recommendation change.
2026. 03. 17.LowBUY4 months ago
Chardan Capital: Buy
US analyst rating / recommendation change.
2026. 03. 17.LowBUY4 months ago
D. Boral Capital: Buy
US analyst rating / recommendation change.
2026. 02. 18.LowBUY5 months ago
D. Boral Capital: Buy
US analyst rating / recommendation change.
2026. 02. 02.LowBUY6 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 01. 21.LowBUY6 months ago
D. Boral Capital: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $15.75 · 6 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.

Sector: Healthcare
Industry

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 11.	After market close (AMC)	$-0.36	—	—	$121.67K	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$-0.44	—	—	$257.88K	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-0.8	—	—	$3.55M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-0.54	—	—	$3.55M	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	61,584	$357.19K	0.00%	—	New position
2	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	37,681	$148.46K	0.00%	—	New position

Coya Therapeutics, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 04. 10.	D. Boral Capital	—	Maintain	Buy → Buy	—	D. Boral Capital: Buy
2026. 03. 23.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 03. 20.	D. Boral Capital	—	Maintain	Buy → Buy	—	D. Boral Capital: Buy
2026. 03. 17.	Chardan Capital	—	Maintain	Buy → Buy	—	Chardan Capital: Buy
2026. 03. 17.	D. Boral Capital	—	Maintain	Buy → Buy	—	D. Boral Capital: Buy
2026. 02. 18.	D. Boral Capital	—	Maintain	Buy → Buy	—	D. Boral Capital: Buy